TP53 and neoplasm: Based on the predictions of our ASCN+SNV model, we identified 99 genes where the proportion of gains was higher in the HRD+ predicted samples, with interesting examples such as GATA3 or PIK3CA and 361 genes where the proportion of losses was higher, including well‐known tumour suppressors such as BRCA2, BRCA1, TP53 and MAP3K1, revealing the importance of LOH events paired with mutations.